In a plenary session at ENDO 2022 titled “Novel nonstatin therapies for LDL cholesterol lowering,” chaired by Anne Goldberg, MD, FACP, and Lisa Tannock, MD, several experts discussed the current clinical status of novel nonstatin, low-density lipoprotein cholesterol (LDL-C)-lowering agents.
PCSK9 inhibitors (John Stafford, Vanderbilt University Medical Center, Tennessee)
Dr Stafford’s...
